CDDF is excited to announce newly elected board members and officers appointed at its first General Assembly since its establishment as a non-profit association in Belgium that took place on 9 June 2020.
The CDDF wishes to thank its outgoing board members, Prof. Leif Hakansson and Prof. Max Scheulen, for their tireless efforts and dedication to CDDF over the last few years.
Prof. John Smyth has replaced Prof. Leif Hakansson as chair of the Board of Directors for a three-year term. We warmly welcome Prof. John Smyth in his new role.
We also warmly welcome incoming board member, Prof. Eva Skovlund; incoming deputy chair, Prof. Ruth Plummer, replacing Prof. John Smyth; and incoming Director of the Board, Dr. Catarina Edfjäll.
Eva Skovlund, Professor of medical statistics at the Norwegian University of Science and Technology in Trondheim, has ten years of regulatory experience in drug licencing at the Norwegian and European Medicines Agencies.
Ruth Plummer, Professor of Experimental Cancer Medicine at Newcastle University, specialises in treating patients with melanoma and directs the Sir Bobby Robson Cancer Trials Research Centre in the UK.
Dr. Catarina Edfjäll looks back on 25 years of experience in the pharmaceutical industry with a strong focus on regulatory affairs and is motivated by a deep commitment to deliver effective medicine to patients with serious diseases.
The diverse experience and backgrounds of our board members enable the CDDF to represent a range of viewpoints and concerns to best achieve its mission to advance cancer care treatment and delivery.
We recognise the hard work and commitment of CDDF leadership in supporting its mission and are confident of the excellence and knowledge these new leaders will bring to CDDF to further its objectives.
Cancer Drug Development Forum
22 June 2020